Cingulate receives first company-owned U.S. patent for ADHD drug CTx-1301

Cingulate Inc. announced the issuance of U.S. Patent No. 12,653,791 for its lead ADHD asset CTx-1301, protecting the drug's formulation and method of use through December 2042. The patent strengthens the company's intellectual property portfolio as it advances toward potential commercialization of its once-daily treatment candidate.